Integrated Report

Overview

The report presents Shionogi Group's fiscal 2017 performance and its purpose-led strategy as a drug discovery-based pharmaceutical company. The company reported net sales of ¥344.7 billion, launched Xofluza in Japan, and continued work addressing infectious diseases and pain/CNS disorders. Its sustainability coverage includes CSR, antimicrobial-resistance initiatives, EHS management, and a goal to reduce CO2 emissions by 33% from the fiscal 2005 benchmark by fiscal 2020.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2017-2018
Period: 1 April 2017 – 31 March 2018
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment
Basis

Assurance

Level
Standard
Scope
Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services